

April 5, 2022



LEADING GLOBAL MEDICAL CANNABIS COMPANY KHIRON PUBLISHES CLINICAL STUDY ON THE EFFECTIVENESS OF ITS PRODUCTS AT CONTROLLING CHRONIC PAIN

Data Substantiates Company's Position as a Global Leader In Health Care Solutions

Key findings in the study include:

- 9 out of 10 patients reported some degree of improvement of their chronic pain.
- 7 out of 10 reported an improvement larger than 50% after 4 weeks of treatment.
- 7 out of 10 patients did not experience any adverse effects related to the treatment. Reported adverse side effects were mild and transient, fading after 12 weeks.

TORONTO, April 5, 2022 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), the global medical cannabis leader expanding throughout Latin America and Europe, has published in the international peer-reviewed journal [Frontiers in Pain Research](#) the results of its first clinical study on the use of medical cannabis prescribed to Colombian patients in treating chronic pain. This is the largest study of its kind in Latin America, and the first published clinical evidence on the effectiveness and safety of Khiron's THC and CBD oil-based cannabis formulations, the two most prescribed products at Khiron's Zerenia Clinics in Colombia. This is reassuring data for prescribing physicians and health insurance providers on the efficacy, safety, and cost-effectiveness of the Khiron's products to treat chronic pain. Frontiers journals rank among the most influential in their academic fields based on total citations and ranks as the 3rd most-cited publisher among the 20 largest publishers.



The study, a joint effort by medical researchers from Khiron Life Sciences and doctors from Zerenia Clinics in Colombia and Europe, captures patient-reported outcome measures ("PROMS") and adverse effects in a large cohort of 2112 adult patients diagnosed with chronic pain of diverse etiology. Between May and September 2021, patients received adjuvant treatment with Khiron's oral oil-based cannabis formulations at the Latin American Institute of Neurology and Nervous System (ILANS-Zerenia) in Bogotá, Colombia.

"This study, based on Khiron's medical products, is critical to reassure physicians and health insurance providers of the efficacy of medicinal cannabis to treat chronic pain. The global impact and economic burden of chronic pain in our society, mounting medical evidence will increase access to cannabinoid-based medicines worldwide." says Alvaro Torres, Khiron CEO and Director. "The recent vote in the US House of Representatives promoting medical research on cannabis clearly shows the pressing need to develop effective and safe cannabis-based medication for suffering patients worldwide. With this and upcoming studies, Khiron will continue to stand above in the field of medical research and to expand the access for patients in those jurisdictions in which we are present".

Guillermo Moreno-Sanz, the first author of the study and Global Scientific Director of Khiron Life Sciences adds, "We believe these findings to be generalizable across patient populations, considering that our results are extremely well-aligned with those reported by researchers working with similar clinical populations in nations with long-standing medicinal cannabis access programs, such as Israel and Canada."

This study is groundbreaking for Khiron as most observational and experimental studies investigating the efficacy of medical cannabis for pain management are of relatively short duration and use a disparity of cannabinoid-based products, routes of administration, and dosing regimens. This study is differentiated as it describes the short-, mid- and long-term

efficacy and safety of two monovarietal formulations containing THC and CBD in different ratios (1:1 and 1:25, respectively), and investigates the contribution of patient's sex, and age. Most participants were female (76.1%) with an average age of 58.7 years old. One third of the participants were elderly (>65 years old).

As Khiron continues to expand its research and business globally through Latin America and Europe, additional studies are expected to continue to demonstrate the Company's business model, creating a 360-solution for health care providers, insurance companies, and patients to benefit from the prescription and positive health outcomes from medical cannabis.

About Khiron Life Sciences Corp.

Khiron is a leading vertically integrated international medical cannabis company with core operations in Latin America and Europe. Leveraging wholly-owned medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and agricultural infrastructure to drive prescriptions and brand loyalty with patients worldwide. The Company has a sales presence in Colombia, Peru, Germany, UK, and Brazil and is positioned to commence sales in Mexico. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and Board of Directors.

Visit Khiron online at investors.khiron.ca

Linkedin <https://www.linkedin.com/company/khiron-life-sciences-corp/>

Cautionary Notes

Forward-Looking Statements

This press release may contain certain "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Annual Information Form which is available on Khiron's SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

 View original content to download multimedia <https://www.prnewswire.com/news-releases/leading-global-medical-cannabis-company-khiron-publishes-clinical-study-on-the-effectiveness-of-its-products-at-controlling-chronic-pain-301517698.html>

SOURCE Khiron Life Sciences Corp.